Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jeong-Ho Chae
With
Ybrain Inc.
Patients were randomized to receive either real or sham-tDCS as well as anti-depressant drugs. tDCS was applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC). Patients visited the hospital to get tDCS administrations 5 days a week for 2 weeks. They were evaluated every 2 weeks.
Age
19–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a diagnosis of a major depressive disorder as confirmed by the SCID-IV and MINI (without psychotic features)
Greater than 22 points of Montgomery-Asberg Depression Rating Scale
Aged 19 to 65.
Has provided informed consent
Has received Escitalopram as a combined antidepressant during the study period
You may not be if
Has other mental disorders diagnosed by Axis-I, except major depressive disorder (However, subject who is diagnosed as both major depressive disorder as well as anxiety disorder can participate the study.)
History of suicidal attempt in the last 6 months
Diagnosed with bipolar or psychotic major depressive disorder
Diagnosed with other depressive disorders: dysthymic disorder, and depressive disorders that are not elsewhere classified.
Has hypersensitivity to Escitalopram ingredients
A score of 5 or greater for the question #10 in MADRS
Diagnosed with closed angle glaucoma or has a history of glaucoma.
History of participation in other clinical trials within 30days.
A major and/or unstable medical or neurologic illness
Currently taking substances pimozide
Pregnant or has a positive pregnancy serum test.
Clareo Health | Effect of Self-administered tDCS in Patients With MDD
